Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Camurus, Audiocast with teleconference, Q3'24

By Inderes11/7/2024, 1:00 PM
Camurus

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Operator
00:01 - 00:16

Welcome to the Camurus Q3 report for 2024. During the question-and-answer session, participants are able to ask questions by dialing pound key five on the telephone keypad. Now we'll hand the conference over to CEO Fredrik Tiberg. Please go ahead.

Fredrik Tiberg
00:17 - 03:13

Thank you so much. And hello, everyone. Welcome to our Q3 2024 earnings call today. Before starting, please note our forward-looking statements. The agenda today, like previous quarters, includes a short summary of third quarter business highlights, followed by a review of our financial performance. And then we will go into commercial and R&D updates and finish off with the Q&A. I'm joined in today's call by our CFO, Jon Garay Alonso and Chief Commercial Officer Richard Jameson. So for those of you who have seen our report today. We had a solid third quarter with strong profitability and operating performance. Our revenues grew by 38%, and by 41% at a constant exchange rate year-on-year, excluding a one-time revenue in 2023, to a total of 480 million SEK. SEK profit before tax increased by 125% to 165 million SEK in Q3. Our best results so far, again excluding the one-time milestone based on the performance and results year to date, we have raised our outlook for the full year 2024, particularly with regard to profit performance. Our cash position at the end of the quarter increased to 2.75 billion SEK, again with no debt in the company. We continued focusing on commercial execution, with Buvidal sales growing nicely by 22% year on year to 428 million SEK. In the US during the quarter, Brixadi net sales increased by 39% year on year or quarter on quarter. I should say sorry about that, resulting in a royalty contribution of 58 million SEK to Camurus. Our R&D pipeline advanced with positive Phase 3 results from our ACROINNOVA II study. Our US NDA progressed to the labeling stage. However, after the quarter, we received a CRL from the FDA regarding a CGMP inspection at the third-party manufacturer, which is currently pending classification. And we expect to get clarity about this by early December. In parallel with the US NDA process, the regulatory MAA review moved forward in the EU. Additionally, preparations for the first clinical study of monthly semaglutide depot CAM2029 were completed. Based on the strong performance year to date, Camurus remains on track to deliver its 2027 vision. And with this, I'll hand it over to John for a financial review.

John
03:14 - 06:48

Thanks a lot, Fredrik, and good afternoon, everyone. During the quarter, Camurus continued its development, delivering a strong financial performance, and I would like to share now the key highlights of this quarter. At the end of the quarter, Camurus achieved 480 million SEK in total revenue, compared to 384 million SEK in the same period the previous year. Excluding 36 million SEK one-time milestone revenues related to Brixadi approval by the FDA in the US in 2023, company revenues grew by 132 million SEK, delivering a growth of 38% versus the same period last year, which is in the high range of provided guidance for this year. Buvidal sales reached 421 million SEK, growing 22% versus the prior year and 5% versus the prior quarter. Swedish kronor appreciation has negatively impacted reported figures by two points on a year-on-year basis and four points versus the prior quarter. Brixadi sales in the US represented a 58 million SEK royalty income in the quarter, representing a 45 million SEK improvement versus the prior quarter. Company profit before taxes was 165 million SEK, achieving an earnings per share after dilution of 2.16 kronor, equivalent to a profit after tax of 129 million SEK in the quarter. Finally, our cash position progressed positively during the quarter and remains strong, ending at 2.75 billion SEK. Moving to the next slide, we can see the main components of our profit before taxes. Company gross margin reached 93% in the quarter, excluding one-time milestones. Revenue impact. It represents an improvement of 222 basis points versus the same period last year, driven by three major factors. Firstly, supply chain efficiencies driven by Buvidal volumes represented 163 basis points. Secondly, 100 basis points are driven by Brixadi royalties. And thirdly, currency effects represented a negative impact of 41 basis points. Total opex reached 304 million SEK, representing a 21% increase versus the same period last year, driven by the following factors. Marketing and distribution investments support market penetration in our own territories. Expansion of Buvidal into new markets and US operations grew by 19% to 112 million SEK. Administrative expenses aligned with corporate evolution to substantiate company development grew 155% versus the same period last year, reaching 27 million SEK. R&D investment reached 163 million SEK, growing 10% versus the same period prior year, driven by progress in our preclinical and clinical pipeline. Company profit before taxes reached 165 million SEK, excluding one-time milestone revenue impact. This represents an improvement of 92 million SEK, increasing 125% versus the same period last year. Company cash position at quarter end was 2.75 billion SEK. Camurus improved its cash position by 184 million SEK in the quarter, driven by the following four factors. Firstly, company operations generated 134 million SEK. Secondly, working capital generated 16 million SEK.

Unknown 1
06:48 - 06:48

16 million SEK.

John
06:48 - 07:53

Driven mainly by accounts receivable reduction. Thirdly, financing activities driven by the exercise of the stock option program delivered 45 million SEK in cash. And finally, the company invested 6 million SEK in technological activities; as of the end of the quarter, Camurus has no debt. All in all, Camurus closes the third quarter with a strong operational performance and solid financial position. As a consequence of such strong performance year to date, thank you for your expectations. Camurus' outlook for total revenue was increased to the range of 1810 to 1880 million SEK, up from the previous range of 1730 to 1840 million SEK, with profit before taxes estimated in the updated range of 450 to 510 million SEK, up from the prior range of 330 to 450 million SEK. Additionally, the company is on track to deliver the long-range plan vision shared at Capital Market Day celebrated in September 2022. Having said that, I would like to pass the word to Richard. Thank you everyone for your attention.

Richard
07:54 - 10:43

Thank you, John. So, I'll start with an update on the Camurus markets and then move to Brixadi in the US. So in the Camurus markets, the third quarter saw further development of Buvidal, reaching 421 million SEK, a 24% year-on-year growth at constant exchange rates, and 6% ahead of the previous quarter. We estimate there are 56,000 patients on treatment at the end of the quarter, a net increase of about 3,000 patients. Growth was seen across our markets, in particular Germany and the UK, which saw good progress as we continue to implement new initiatives to accelerate patient recruitment. Other markets were slightly softer due to the holiday season restricting patient recruitment; however, as expected, they picked up at the end of the quarter as staff returned to work in all countries. Penetration is growing in both custodial and community settings. In Australia. The new distribution and payment system, following the recent government changes, was fully implemented. This is a positive change as patients have reduced out-of-pocket costs for administration, and we're now focusing on addressing bottlenecks for patient recruitment by expanding pharmacy administration and increasing engagement with primary care physicians. We continue to address reimbursement hurdles in new markets and expect at least two of these to be finalized in Q4, with launches soon after in early 2025. In addition, we have four markets undergoing regulatory reviews with anticipated outcomes in 2025. In 2023, we made a donation to support patients in Ukraine during the conflict and have now received a positive assessment of this experience and how Buvidal has supported patients during this time. We're now exploring ways to continue to support patients in the country. Now moving across to the US. Q3 continued the sales development of Brixadi, demonstrated by the increasing royalty to 58 million SEK, a growth of 39% at constant exchange rates compared to the previous quarter. The increasing market share comes primarily from the capture of patients from sublingual buprenorphine products, and the remainder from transfers from other long-acting injectable products, or from direct initiations. As we've communicated before, the opportunity in the US is significant, with an estimated more than 6 million people with an opioid use disorder diagnosis and an estimated 1.8 million treated with sublingual buprenorphine. The peak market potential for Brixadi is significantly above 1 billion USD, which only represents 6% market penetration of existing treated patients. Finally, we continue to be very active in Congresses and scientific meetings to share the evidence base for Buvidal and have a full schedule of key meetings for the rest of this year and in 2025. Additionally, we have further publications from across geographies as we expand the evidence base for Buvidal and Brixadi in both community and custodial settings. And on that brief update, I will hand back to Fredrik.

Fredrik Tiberg
10:43 - 19:18

Thank you so much, and over to an update on our core R&D programs. During the second quarter, we advanced our late-stage clinical development programs of Octreotide Subcutaneous Depot CAM2029, targeting three indications: acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease. Starting with acromegaly and the ACROINNOVA program in July, we received positive Phase 3 results from a 52-week open-label ACROINNOVA study evaluating the safety and efficacy of CAM2029 in newly enrolled patients and rollover patients from ACROINNOVA One. Key findings and observations in this study included a safety profile consistent with that of the current standard of care with first-generation somatostatin receptor ligand products. Increased biochemical response rates in the overall population after 52 weeks of treatment with CAM2029, again compared to the standard of care at baseline and consistent with ACROINNOVA one. We also saw improvements in symptom treatment, satisfaction, and quality of life scores versus standard of care at baseline. Recently, the main results from ACROINNOVA One have been accepted for publication in the Journal of Clinical Endocrinology and Metabolism, and we expect them to be published very soon, if not already. And after that, we'll move over to the GEP-NET program. And I intend to share an update on the progress of the pivotal Phase 3 SORENTO study. As a reminder, SORENTO is the largest prospective, randomized, controlled trial of a somatostatin receptor ligand in gastroenteropancreatic neuroendocrine tumors. The study is designed to assess superiority in progression-free survival of CAM2029 compared to an investigator's choice of standard of care with Octreotide or Lanreotide. Ujjal. A broad population of GEP-NET patients with advanced metastatic, inoperable, well-differentiated neuroendocrine tumors of grades 1 to 3 have been included in this study. The trial is powered to a hazard ratio of 0.65, and the primary results will be assessed after 194 PFS events. Progression-free survival events. Secondary outcomes include overall survival, multiple patient-reported outcomes, and, of course, safety. SORENTO is a global study with a geographic distribution of patients as seen in this slide. All in all, we included 332 patients across 12 countries, which is 10% above our target recruitment due to high interest and rapid inclusion. Having reached an average treatment time of 15 months in the study, we recently performed an updated analysis of the number of tumor progression events or deaths in the trial. This was done to guide the expected timing for reaching the target number of PFS events for reading out the primary endpoint. The analysis indicates a longer than expected progression free survival (PFS) for the patient population in the SORENTO trial, a majority of whom had more advanced disease with grade two neuroendocrine tumors. The rest were grade one, and a few were grade three. These patients have better than expected tumor control in the study. The estimated timing for reaching the target number of PFS events has been updated from the first half of 2025 to late 2025 or early 2026. The next external update on the SORENTO trial is planned for Q1 2025. Moving over to polycystic liver disease and the POSITANO study. POSITANO is a 52-week randomized controlled trial assessing the efficacy and safety of CAM2029 in two dose groups versus placebo. The primary endpoint is height-adjusted liver volume, and secondary endpoints include PLD symptoms measured using a newly developed patient-reported outcomes tool. Total volume. Treatment satisfaction. Quality of life and safety. Patients who complete the randomized phase have the option to enter a long-term extension, which has been extended to 32 months of open-label treatment. Moving to the next slide. A total of 71 patients with symptomatic Polycystic liver disease (PLD) have been included in the POSITANO study. The last patient entered the study in February of this year. More than half have completed the randomized treatment phase and switched over to the open-label extension. Top-line results of the core randomized phase of the study are expected in the first half of 2025. Aside from clinical progress during the quarter, we also received a recommendation for orphan drug designation for CAM2029 in autosomal dominant polycystic liver disease from the EMA, which has now been formally adopted by the European Commission. So, as a summary, here is the updated timeline for our three pivotal clinical programs for CAM2029. Moving over to regulatory updates and an overview of acromegaly. As you're aware, we received a CRL from the FDA on the 21st of October. That is a complete response letter issued after having late-stage ongoing labeling discussions with the agency. The CRL was solely related to observations during a cGMP inspection at a third-party manufacturing facility and did not raise any concerns relating to CAM2029, including safety, efficacy, or quality. Unfortunately, the timing of the inspection precluded resolution of the observations by the PDUFA date. Since the inspection, the manufacturing team has addressed all observations and is expecting a classification by early December. Providing this satisfactorily addresses the agency's observations, Camurus will rapidly resubmit the NDA for review. We are working towards a scenario of class one resubmission with an anticipated two-month review period. Otherwise, a six-month timeline would be applicable. Finishing off with some early R&D developments, we have completed preparations for a randomized, dose-escalating, multiple-dose Phase 1 study of monthly semaglutide in overweight and obese participants and are expecting the first subject's first visit early in the next year. Preclinical assessments of other long-acting GLP-1 agonists have also been performed with promising results, along with the starts of two new collaboration projects for long-acting peptides using the FluidCrystal technology. So with this short, um, run-through of activities in the third quarter and wrapping up, I'm pleased with the continued performance of our teams and the progress that we have made during the quarter, which has resulted in robust profitability, solid double-digit growth of Buvidal and Brixadi launch, continuing to progress in the US, regulatory progress for CAM2029 and acromegaly, along with early pipeline progress, including the CTA submission for our once monthly semaglutide. As a result of the solid performance to date, we have raised our outlook for the full year 2024. And with that as my last note, thank you for your attention and please take over the call for Q&A.

Operator
19:19 - 19:30

Thanks, Frédéric. As a reminder, if you wish to ask a question, please dial star. Pound key. Five on your telephone keypad. The first question comes from the line of Christopher Uhde from Seb. Please go ahead.

Unknown 2
19:35 - 19:58

Christopher Uhde from SEB. Sorry. Thanks for taking my questions. No problem. So my first question is on the US market dynamics; what can you tell us about how that looked during Q3, especially with respect to long-acting injectables versus sublinguals, and maybe reasons for your confidence in a strong Q4?

Fredrik Tiberg
20:00 - 20:44

Yeah, I think overall, if we're looking at the segment, the third quarter was slowing down slightly in terms of the growth pattern. And we saw, of course, progressing in other areas even though other products did not have a strong performance in the third quarter. And we believe this is partially due to the seasonality over the period, and we have no information suggesting that we should not have a stronger continuation of the year in Q4. And that is also based on the fact that we saw a pickup in September.

Unknown 2
20:47 - 21:08

Okay. Great. Thanks. And then, we haven't historically seen clear seasonality in Europe, even though it obviously makes perfect sense that there must be some. Why are we seeing it more clearly now? And then, are you still expecting Buvidal to be stronger in Q4 than in earlier quarters this year?

Fredrik Tiberg
21:10 - 21:29

Yeah. I think, regarding the seasonality for Buvidal, sometimes it has been, what should I say, disguised by single orders, which, if there is a single country order that comes in, it may. But we see overall in-market sales are relevant.

Unknown 2
21:39 - 21:39

Um.

Operator
21:41 - 21:46

It seems we have lost part of this line. Are you there? Christopher?

Fredrik Tiberg
21:46 - 21:47

You hear me?

Operator
21:47 - 21:49

I'm here. And now we hear you again. Yes.

Unknown 2
21:49 - 21:49

Now I can hear you.

Unknown 3
21:52 - 21:53

Did you, uh.

Unknown 2
21:53 - 22:00

I think we lost you. We lost you at seasonality where sometimes it is disguised by single orders from one country or another.

Unknown 3
22:00 - 22:01

Yes, that.

Fredrik Tiberg
22:01 - 22:05

That was, uh, Richard, do you want to follow up on the rest of the question? Yes.

Richard
22:05 - 22:21

I mean, the Q3 growth was the same as Q2, which was the same as Q2 against Q1. So, we have the underlying growth there. It certainly is seasonal there. We saw a pickup at the end of the quarter, as we usually do in September. So we have confidence for Q4.

Unknown 2
22:24 - 22:45

Okay. Um, and then I guess, why was there a sequential drop in marketing and distribution? And does this CRL impact your plans for the timing of the ramp up of SG&A? Uh, during the rest of the year? And then, related to that? Well, yes, I guess that's my last question. Thanks.

John
22:46 - 24:00

Yes. So, thanks for the question, Christopher Uhde. So just to answer you on one hand, from a total opex perspective, although U.S. marketing and distribution have historically been consistent with past patterns. Historically, the opex of the company in Q3 of 2023 and 2022 was lower than in Q2. There are mainly two reasons behind it. One is seasonality. Our employees go on holidays, and our consultants also take their holidays. So we don't receive invoices from third-party consultants during the holidays of our employees. They go against the accruals that we are reversing. It is usually lower, and you can see the patterns in the past. This year, the pattern is also impacted by the fact that in Q2, our employees exercised around 670,000 stock options, the cost of which is no longer present in Q3. So when we are comparing Q3 to Q2, that's an impact on the positive side. In spite of that, we have been increasing our investment in the US, and in fact, we are still committed to continue investing in the range of 0.60 to 0.65 billion SEK at the end of the year in R&D, as we explained in our guidance.

Unknown 3
24:02 - 24:05

And I believe that covers it, thank you very much. Yeah.

Fredrik Tiberg
24:05 - 24:14

Sorry. Please continue. No.

Operator
24:16 - 24:24

Sorry. The next question is from Brian Balchin from Jefferies. Please go ahead. Brian.

Unknown 4
24:24 - 25:10

Hey guys, thanks for the question. Yeah, thanks for the question. Um, just a clarification on the closing. It seems like you were able to address those manufacturing issues faster than expected. So when you say outcome in December, I just wanted to clarify if that means you've already resubmitted your BLA, because it sounds like you haven't. Um, and then if you can just give us a sense of whether you're expecting class one or class two, I think the base case is class two for a potential approval. Additionally, regarding the GEP-NET delay. Um, can you just share your thoughts on how we should be interpreting that? Just as I'd thought, patients would be accruing events at a faster pace, given the skew to the more severe grades two and three. Yeah. Thank you.

Unknown 3
25:12 - 25:13

Yeah.

Fredrik Tiberg
25:13 - 25:13

Um.

John
25:15 - 25:20

So the first question was a clarification about what we expect last.

Unknown 3
25:20 - 25:20

Oh yeah.

John
25:21 - 25:21

Yes, yes, yes.

Fredrik Tiberg
25:22 - 28:34

So I mean, what happened, Brian. Sorry. Indeed, the inspection occurred very close to the PDUFA date. And when you do a cGMP inspection, typically the agency has a 90-day period for addressing the response to the observations and then issuing a classification. And the classification is, of course, the end result. So what we are waiting for is that the manufacturer has responded according to the normal schedule for these inspections. And 90 days will be at the beginning of December when they will receive their classification, and provided that this classification is satisfactory, which we have to presume, then we will be able to resubmit the NDA. And as there are no other issues relating, it will just be an update of the safety database to a new, updated date. So that's basically the progress. And our base case is that this would be a class one resubmission. So a two month review period. Should the agency decide that another inspection is necessary, then it's much more likely that it would be a six month review period. That's my understanding. So when it comes to the discussion around GEP-NET and progression-free survival. So when we did our analysis to guide for reaching the target number of events, we based that on historical matched controls. So we have looked at all the studies that we have been able to get data from, both published and unpublished, and we have made our comparison to patients with a similar profile in terms of Ki-67 and proliferation or grade, for that matter. So, that has been the outset. In the study, of course, we compared, for instance, to clarinet; we had a majority of patients that reported being grade two and even some grade three patients, whereas in other studies, including band clarinet, they exhibited much lower disease severity, with only about 20%. And I should also clarify that we have patients with a Ki67 above ten. So, all the way up to over 20, which you could say is the proliferation rate of the tumors.

Unknown 3
28:38 - 28:42

Is that clear? Is that clear?

Unknown 4
28:43 - 28:45

Yes, it is. Yeah. Thank you, guys.

Operator
28:47 - 28:50

The next question is from Viktor Sundberg of Nadia. Please go ahead.

Unknown 5
28:55 - 29:43

Yes. Hi. Thanks for taking my questions. So first on Brixadi, there is a bit of a disconnect, I guess, between the wording from the Indivior interviewer that you're being impacted by competition from Brixadi. But looking at your numbers, they don't really imply that you're taking massive market share or that your partner is, in this quarter at least, or taking market share in a way that would lead one to believe that Indivior is losing to you so badly that you need to guide differently on Sublocade. But I guess that has to be the case because there are no other main competitors like Vivitrol, as you know, which has quite an insignificant market share outside of the prison system. So maybe if you can help us understand what you're seeing in the US at the moment or what you hear from your partner in terms of how you are eating into the market share of long-acting buprenorphine. I'll start there. Thanks.

Unknown 3
29:43 - 29:44

I think.

Fredrik Tiberg
29:44 - 30:36

First of all, I mean, the majority of patients are not coming from another long-acting injectable, but they're actually coming from the sublingual segment. So, I would say up to 70% of patients are coming from sublingual treatment, which we are very happy with. So in that sense, you're completely right that we are not eating up the long-acting injectable market, at least not numerically. So, so that's a positive evolution, I think. Overall, I think that the third quarter, as I mentioned, considering the entire market, was a slower quarter. And that's an important comment. In addition to that, John, do you want to say anything else about this? Richard.

John
30:36 - 31:25

No, I understand the point. Victor is doing well as we grow. We are penetrating with Brixadi, but we cannot comment on the data another company is doing. We continue to penetrate the market. We are gaining market share. In fact, I think one of your colleagues, one of the market analysts, has published this morning an estimate of the number of patients already in the range of 15,000 patients. And these are the data we are tracking. So, we can discuss our market penetration and our estimated market share but not about what other companies are discussing. Victor. We are sure that we will continue to penetrate the market, having estimated 15,000 patients, as suggested by one of your colleagues. I think it is a decent amount of patients for the product in the market after one year.

Fredrik Tiberg
31:26 - 32:08

Overall, I think the general sense we are getting from the market is positive and we are expecting Q4 to be strong. How strong? I cannot say at this time point. We will just have the numbers and I think we'll be able to give more important, I would say, long-term indications after the next quarter. We're still early on, I believe, in the development, but the US market continues to be very attractive, and I think the possibilities are significant. It's a matter of execution. Commercial execution.

Unknown 5
32:10 - 32:38

Okay. And my second question is also on SORENTO. Um, so I'm a bit worried here that we have a poor understanding, or at least from looking at historical data, of how well the controller will perform in your study design. But can you perhaps help us understand what exactly you have assumed when you designed the study, in terms of median PFS that we should expect from the physician's choice of other long-acting somatostatin analogs?

Unknown 3
32:39 - 32:40

Yes, definitely.

Fredrik Tiberg
32:40 - 33:12

Yes, we can do that. I mean, our assumptions from the start, so to speak. When we powered the study, as I said, it was a 0.65 hazard ratio. And we were assuming an 18-month PFS in the control group. And obviously, then you can translate that into the PFS in the active arm. Which will then be.

Unknown 3
33:13 - 33:13

Yeah.

Fredrik Tiberg
33:15 - 33:16

Is that okay?

Unknown 5
33:17 - 33:35

Yeah. That's clear. And maybe I'll sneak one in on guidance also. What's the major reason for upgrading your sales guidance given the slightly softer Q3? Is it forecasted for Brixadi sales to tick up in Q4, or is it Buvidal ex-U.S. that makes you confident enough to raise top line guidance? that make you confident enough to raise top-line guidance? Thanks.

John
33:37 - 34:08

Uh, in the end, the increase in the top line is very modest. What strongly reinforces our belief is the performance of both Buvidal and Brixadi. That is not only one main driver, as you try to point out, it's both products. They are the same product, but both of them have been performing equally strongly since the second half of this year. So, it is both of them. But again, the top line increases. I think someone has written this morning that it is modest.

Unknown 5
34:10 - 34:11

Yeah. Thank you.

Operator
34:13 - 34:17

The next question is from Mattias Häggblom of Handelsbanken. Please go ahead.

Unknown 6
34:21 - 35:24

Yeah. Thanks so much. I have two questions, please. Coming back, firstly to the phasing of opex. I thought one of the consequences of the CRL for CAM2029 would be that you pause the build-out of the US organization during the remainder of '24 to ensure that you get the FDA approval early in '25 and then you speed up that process. But I guess my first part of the question is, what does the guidance really imply? Because it sounds to me that you're sticking to what you've said before in terms of commercial build-out, as well as the R&D spend at a similar level compared to last year. And then, the second question related to long-acting GLP-1 for obesity. What comments do you have in relation to Novo's recent choice to partner with Ascendis Pharma to develop a monthly semaglutide for obesity using Ascendis's TransCon technology? And would you mind comparing and contrasting TransCon to FluidCrystal as a platform? Thanks so much.

Unknown 3
35:24 - 35:24

Yeah.

Fredrik Tiberg
35:26 - 35:31

Yeah. Um, I mean, do you want to start with the first question, John, or discuss the opex?

John
35:32 - 35:50

Yeah. So regarding the impact of our opex estimates for Q4, we have always been transparent that the Salesforce team would join upon a positive outcome of the PDUFA date. And we were expecting the 21st of October. And I think when we were discussing the prior earnings call, we were sharing.

Unknown 1
35:50 - 35:51

That.

John
35:51 - 36:38

They would be joining in mid-November. Second half of November. So the impact of postponing this is modest in our estimate of the opex for this year, because it's only one month of the sales team on the field. Let’s not forget that we have already made public that many of the strategic positions in payer access and market access are already on board. So that's a limited impact in our opex estimate. Yes, we are committed. And to invest 6.65 billion in R&D following the development of our pipeline, I think we are already at 516 million SEK as of the end of September. So we think we are going to deliver it. So, this is a brief summary of our Q4 investment.

Unknown 3
36:39 - 36:39

And I think.

Fredrik Tiberg
36:39 - 38:16

We should also comment that we are really continuing to invest in the US build-up. As John mentioned, we are not onboarding the sales force. However, we have received very positive signals from those we have identified, and their continued interest ensures we will onboard them as quickly as possible. But we have actually built out the organization and added new employees since the CRM. So we have a very strong focus and believe in that in the US. With regards to the agreement between Novo and TransCon, I guess I have only seen some comments from a press release that was shared with me by an investor. And I mean, we have our focused strategy in this field. Comparing the TransCon technology to the FluidCrystal technology, which is lipid-based, as you know, whereas the TransCon technology is based on a hydrogel. To my understanding, it requires the formation of chemical bonds. Um, it's been successfully applied to at least two approved products at this stage. So the product and also, um, human growth hormone. I think it's an interesting, yet different, technology. But when it comes to the agreement between the two parties you referred to, I don't have a comment. We are very clearly focused on our own agenda at Camurus.

Unknown 6
38:18 - 38:40

That's very helpful. Thanks so much. One quick follow-up. Conceptually, how should we think about R&D spending linked to SORENTO, given that it's now assumed to extend into late 2025, early 2026? Um, you know, is the vast majority of the cost already accounted for, or, you know, help me conceptualize that?

Unknown 3
38:41 - 38:42

So when you.

John
38:42 - 38:44

When you are talking about the vast majority of the.

Unknown 1
38:44 - 38:45

Cost.

John
38:45 - 39:15

It depends on which costs you are assuming. But internally, our assumption is that the latest part of the milestones will go with the extension of the project, and we will have continued running expenses for another 6 to 9 months. Bear in mind the statement Fredrik made in his letter. So yes, we are going to have additional running expenses, but we are well equipped to finance and invest in them, and our vision for 2027 remains intact. It's not changing.

Unknown 6
39:18 - 39:19

Thanks so much.

Operator
39:20 - 39:25

Next question from Dan Akschuti of Pareto Securities. Please go ahead. Your line is open.

Unknown 7
39:29 - 39:55

Congratulations on the continuous progress. I just have one question remaining, and that would be if you can share that with us. What kind of patients are you attracting in the US who have not been previously treated, to better understand the uptake in that larger market you mentioned? How is Brixadi penetrating into these new patient categories?

Unknown 3
39:56 - 39:56

Thank you.

Fredrik Tiberg
39:59 - 40:41

So thank you so much. That's a good question, Dan. Unfortunately, I can't provide a detailed response to that. I mean, the focus initially has, of course, been on the switch patients. I believe that this is, you know, your kind of traditional scenario. That's where the large pool of patients is. There are a lot of activities going on in the US. So, I mean, in terms of investigator-initiated trials and so forth, this involves even going into the ER setting. But I would say that at this time point, it's still a small fraction of the overall number, at least from the data that we have seen and to which we have access to public data.

Unknown 3
40:41 - 40:41

Uh.

Fredrik Tiberg
40:41 - 40:49

It's still a small fraction if you're looking at the direct initiations, but it's a big opportunity.

Unknown 7
40:52 - 40:53

Okay. Thank you.

Operator
40:55 - 41:00

The next question from Oscar Haffen Lamm from Bryan Garnier. Please go ahead.

Unknown 8
41:02 - 41:28

Yeah. Hi, team. Thank you for taking my question. Regarding the upcoming semaglutide trial, I'm just wondering how many patients in phase one you plan to recruit. And if you could already guide us on approximately how much that would cost. And then, maybe as a quick follow-up question, um, how do you think in terms of later stage clinical development plans for this trial, for this product? Thank you.

Fredrik Tiberg
41:29 - 41:39

So in terms of the number of patients, I can only refer to the fact that we haven't gone out with any information. But if you look at our similar trials.

Unknown 3
41:39 - 41:40

Trials.

Fredrik Tiberg
41:40 - 42:26

That we have conducted are those escalating trials, and in this case, also with the comparator. You're not talking about ten patients, but rather up towards the 100 number. So, I don't think we have disclosed anything more than that, but that's the order of magnitude. Um, aside from that, we have not gone into our detailed continued development or long-range plans for this. We're conducting the study and will be looking at the next steps, along with the performance of phase one and other ongoing activities in this space.

Unknown 8
42:30 - 42:31

Okay, great. Thank you.

Operator
42:33 - 42:36

The next question is from Erik Hultgård of Carnegie. Please go ahead.

Unknown 2
42:40 - 42:43

Yes. Hi. Thanks for taking my questions.

Unknown 9
42:43 - 43:53

Thanks for taking my questions. I have two, if I may. First, in Buvidal, can you say something about your confidence level in hitting the 100,000 patient target that you've set up for 2026? In the past three years, there has been a consistent increase of approximately three thousand patients per quarter. And I assume hitting that target would require an acceleration to around 5,000 patients per quarter. So, I was just wondering if you could highlight the key catalysts or events to get to that accelerated number of new patient starts. And then, secondly, on Brixadi, I understand and acknowledge that you're not in control of the launch and don't have all the details, but I was just wondering if you could share something about new market and Rx shares for Brixadi compared to Sublocade in the US and how that has changed since the last quarter. Thank you.

Fredrik Tiberg
43:54 - 44:12

Yeah. With regards to the first statement, I'll leave that over to Richard. But I mean, we have not changed. Our target of 100,000 patients remains unchanged. And obviously there are two components of that: penetration and market expansion. So maybe, Richard, you can go ahead.

Unknown 3
44:12 - 44:13

Yeah. I mean.

Richard
44:13 - 44:50

What I can say is that the demand for Buvidal certainly remains high. We see from clinicians and patients that our numbers are growing there. There are some hurdles at the moment that we're addressing around funding and reimbursement in new markets. And I mentioned earlier that we've got some new markets that we think will come over the line at the end of this quarter. So our plan is based on addressing some of those hurdles that free up access, because we know where we have freed up access. The penetration is very high. So you can look at some of the countries like Australia and the Nordics, where there isn't a hurdle. We see high penetration. So our activity now is to address those hurdles so we can grow faster.

Fredrik Tiberg
44:50 - 45:24

And one thing we are doing also in addition to that is that we have a huge opportunity in the methadone market, and we are working now increasingly with a focus on both the methodology for switching patients easily and conveniently, as well as building up that market because we believe that this is a large opportunity going forward here. So, could you repeat that? I didn't hear about the Brixadi comparison you wanted, Eric. I'm sorry, I missed out on that. I'm sorry.

Unknown 2
45:28 - 45:29

No worries.

Unknown 9
45:29 - 45:31

So, my question was basically about.

Unknown 10
45:31 - 45:32

Uh.

Unknown 9
45:32 - 45:32

New.

Unknown 10
45:32 - 45:33

Prescription.

Unknown 9
45:33 - 45:50

Share compared to Sublocade in Q3 compared to Q2. I acknowledge that you don't have all the details. Maybe, but if you can share what information or intel you have from external market research, that would be helpful. Thank you.

Fredrik Tiberg
45:51 - 46:33

Yes. Well, I mean, the market share is growing. It's been established that from a total patient perspective, it is about 20% at this point in the US, which I think is a good number. Um, and higher in what you say, the new-to-treatment group or new-to-treatment population. But I don't think I can share anything more detailed because we are having access to a few data sources and it's difficult to give more precise information at this point. And. But that's the order of magnitude.

Unknown 10
46:36 - 46:37

Great. Thank you.

Unknown 9
46:37 - 46:50

And just to follow up on the methadone issue, sort of. Converting patients from methadone. When do you expect that to happen? Is there a specific event, or will that be gradual progress over the course of the next year?

Fredrik Tiberg
46:51 - 47:35

Yes, we are progressing both from an interaction perspective because, I mean, if you look at the labeling and so forth, it's a bit more cumbersome. The approach right now requires you to reduce your methadone doses before you can switch over to Buvidal or another buprenorphine treatment. And so, there are a lot of activities going on in that area to try to develop the methodology, but that's kind of outside what we are focusing on. And there is a large demand among methadone patients to switch to a long-acting treatment. And I know that it's from. From a commercial standpoint, that's our focus.

Unknown 9
47:39 - 47:40

All right. Thank you so much.

Operator
47:41 - 47:45

Next question from Patrik Ling from Zambia. Please go ahead.

Unknown 7
47:49 - 47:50

Great. Thank you, guys.

Unknown 3
47:50 - 47:51

Just two.

Unknown 7
47:51 - 47:54

Short ones. Um, just wondering. I mean, you.

Unknown 3
47:54 - 47:54

You.

Unknown 7
47:54 - 48:08

Mentioned that there's been an independent safety committee that has looked at safety in the SORENTO trial at six points in time. Have they also, at some point, looked at some sort of futility analysis for the trial?

Fredrik Tiberg
48:09 - 48:22

Um, good question. We don't have any built-in futility analysis in the trial. So they are exclusive. They are exclusively looking at safety data.

Unknown 7
48:24 - 48:55

Okay, great. Understood. Then, my second question is, since you're guiding on pre-tax profit, what are your thoughts on interest rates coming down globally and you have a huge pile of cash? Actually, I don't really understand why you're guiding on pre-tax instead of operating profit, but maybe you can shed some light on how you think we should think about your large pile of cash.

Unknown 1
48:56 - 48:57

That.

John
48:57 - 50:06

You are asking two separate questions. I'm not sure which question you are raising, Patrick, but I will. I will try to reply. It's true. I'm here. I'm listening to you. So sorry for that. But your question is. Indeed, the amount of cash the company is accumulating has solidified our position, and we conducted an ECM in January. The use of proceeds was very transparent. It was written there, and we are doing the job to consolidate GEP-NET as much as we can. We are trying to enhance our capabilities in the manufacturing area and continue the search for assets that can be synergistic to us, that can accelerate our growth, and increase the return on investment of our sales forces because we have some forces with capacity for another product to find these assets. It takes time. It's not difficult to find an asset. It takes time to find the right one with quality. And when this comes, we will be prepared to execute the transaction. So that's our strategy for our cash. Our guiding principles for capital allocation have not changed. They are transparent. So. So that's why we are building up this Patrick Ling.

Unknown 3
50:07 - 50:08

But we.

Fredrik Tiberg
50:08 - 50:11

We appreciate and take your comment into consideration.

Unknown 3
50:11 - 50:14

About. Sorry. Continue.

Unknown 7
50:14 - 50:34

No, sorry. I mean, that was not really what I intended. I mean, it's kind of unusual that you guide on pre-tax because, you know, in your case right now, you have a big pile of cash. And when you do an acquisition, you will probably not have that. So the question is really, why are you guiding on pre-tax rather than on operating profit?

John
50:35 - 51:21

So the question is, when we prepared this year's financials, we thought it would be easier to provide pre-tax because it's closer to the earnings per share, bearing in mind the deferred tax losses that we have on our balance sheet, which is transparent information for any shareholder. The main dynamic on our P&L is gross margin, and we are very transparent in the gross margin performance. I think we have been improving it quarter on quarter, and the second one is cost control, and the third one is cash management. But the cash is temporary until we are able to deliver on what we have promised. So we don't see any big difference. Patrick, on operating results or on profit before taxes. In the end, what we focus on is the earnings per share for the shareholders.

Unknown 7
51:23 - 51:26

It's not difficult to find an asset. Great. Got it. Thank you.

Fredrik Tiberg
51:27 - 51:28

Thank you. Patrick.

Operator
51:30 - 51:36

The last questions. I don't have the name there. Please state your name and company. Your line is open.

Unknown 11
51:38 - 52:04

Thanks. It's James Osborne from Stifel. Just firstly, a clarification. I think you mentioned that 70% of patients transitioning to Brixadi were switching from sublingual formulations. If you could just clarify that, it would be really helpful. And then secondly, just sticking with Brixadi in the US, perhaps if you can give some insight into Brixadi's progress within the criminal justice system versus other channels, as you mention, regarding the switching and new patients, if there's any detail there, that would be helpful. Thank you.

Unknown 3
52:05 - 52:06

Yeah, I think.

Fredrik Tiberg
52:06 - 52:31

In the first case, you know, this is public data from a public data source. So I can confirm that. And when it comes to the second question, unfortunately, I don't think I can provide any granularity regarding the contributions from the different channels at this point. I'm sorry to say, but on the first point, I can confirm your question.

Unknown 11
52:33 - 52:35

Okay, great. Thank you very much.

Operator
52:38 - 52:43

There are no more questions at this time. So I hand the word back to you, Fredrik, John, and Richard for closing comments.

Fredrik Tiberg
52:44 - 53:09

Thank you so much, and thanks, everybody, for your attention today. I particularly want to thank you for coming with great questions, which makes this a much more interesting event. So thank you all for that, and I'm looking forward to the next update in the Q4 call coming up. So hopefully that will be a very strong result as well. So thank you very much.

Operator
53:10 - 53:13

This concludes today's call. You may disconnect your lines.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…